Page 6 - Biotech Investing News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Biotech investing. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Biotech Investing Today - Breaking & Trending Today

AbbVie Announces U.S. FDA Granted Breakthrough Therapy Designation to Telisotuzumab Vedotin for Previously Treated Non-Small Cell Lung Cancer

ABBVie announced today that the U.S. Food and Drug Administration granted Breakthrough Therapy Designation to investigational telisotuzumab vedotin for the treatment of patients with advancedmetastatic epidermal growth factor receptor wild type, nonsquamous non-small cell lung cancer with high levels of c-Met overexpression whose disease has progressed on or after platinum-based therapy. The FDA s BTD program is . ....

News Network , Investing News Network , Biotech Investing ,

Naturally Splendid Closes First Tranche of $2,150,515

Naturally Splendid Enterprises Ltd. announces that it has closed the first tranche of its previously announced non-brokered private placement financing by issuing 71,683,846 Units at a price of $0.03 per Unit for gross proceeds of $2,150,515 with each Warrant entitling the holder to purchase one additional common share for a period of two years from the date of the issue at an exercise price of $0.05 per share.Under . ....

News Network , Investing News Network , Naturally Splendid , Sxv Nsp , Biotech Investing ,

Gilead Announces Clinical Hold on Studies Evaluating Injectable Lenacapavir for HIV Treatment and Prevention Due to Vial Quality Concerns

Pause Due to Concerns About Compatibility of the Vial Type with the Drug Solution Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has placed a clinical hold on the use of injectable lenacapavir in borosilicate vials in all ongoing clinical studies for HIV treatment and HIV pre-exposure prophylaxis . The FDA’s clinical hold is due to emerging concerns about the compatibility of . ....

News Network , Investing News Network , Gilead Sciences , Biotech Investing ,

Lexaria Enters One-Year Media Outreach Agreement with SRAX, Inc.

Lexaria Bioscience Corp. a global innovator in drug delivery platforms announces that it has entered into an advertising and media agreement for media buys and digital marketing with SRAX, Inc. . SRAX will employ leading-edge analytical algorithms to maximize engagement. As consideration for the Services, Lexaria will issue SRAX an aggregate 224,299 restricted common shares from its authorized share capital at a . ....

News Network , Investing News Network , Lexaria Bioscience , Se Lxx , Biotech Investing ,

Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics' TCR Bispecific Program IMA401

Bristol Myers Squibb secures global exclusive license to Immatics’ TCR bispecific program IMA401; companies will collaborate on development with Immatics retaining a co-promotion option in the US Immatics to receive upfront payment of $150 million and additional milestone payments of up to $770 million plus tiered double-digit royalties on net product sales Immatics N.V. a clinical-stage biopharmaceutical company . ....

News Network , Investing News Network , Bristol Myers Squibb , Biotech Investing ,